---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-21-004906"
form_type: "8-K"
ticker: "AURA"
cik: "0001501796"
company_name: "Aura Biosciences, Inc."
filed_at: "2021-11-24T23:59:59+00:00"
generated_at: "2026-06-28T05:28:25.673462+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aura Biosciences Q3 net loss $8.8M; AU-011 data and IPO highlight quarter

## Summary
- Net loss $8.8M for Q3 2021 vs $3.6M YoY; R&D expenses $6.4M (up from $2.9M).
- Cash $81.8M at Sep 30; IPO raised $86.9M gross in Nov 2021 at $14.00/share.
- Final Phase 1b/2 data: 64% tumor control, 71% visual acuity preservation for AU-011 in choroidal melanoma.
- Plans to start AU-011 pivotal program H2 2022; Phase 1a in NMIBC expected H2 2022.
- Added Antony Mattessich to board and Chris Primiano as CBO in September 2021.

## SEC filing metadata
- accession: 0000950170-21-004906
- form_type: 8-K
- ticker: AURA
- cik: 0001501796
- company_name: Aura Biosciences, Inc.
- filed_at: 2021-11-24T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501796/000095017021004906/0000950170-21-004906-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501796/000095017021004906/aura-20211124.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-21-004906
- JSON: https://secwatch.observer/filing/0000950170-21-004906.json
- Plain text: https://secwatch.observer/filing/0000950170-21-004906.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.